Summit Therapeutics Inc.
SMMT
$25.26
$1.305.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 64.38M | 60.31M | 57.45M | 42.50M | 34.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -100.00K | -100.00K | -74.00K | -603.00K | -417.00K |
| Total Operating Expenses | 235.45M | 210.99M | 181.59M | 143.70M | 114.89M |
| Operating Income | -235.45M | -210.99M | -181.59M | -143.70M | -114.89M |
| Income Before Tax | -240.76M | -221.32M | -196.68M | -161.69M | -116.03M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -240.76 | -221.32 | -196.68 | -161.69 | -116.03 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -240.76M | -221.32M | -196.68M | -161.69M | -116.03M |
| EBIT | -235.45M | -210.99M | -181.59M | -143.70M | -114.89M |
| EBITDA | -235.37M | -210.90M | -181.49M | -143.59M | -114.75M |
| EPS Basic | -0.33 | -0.31 | -0.28 | -0.23 | -0.17 |
| Normalized Basic EPS | -0.19 | -0.18 | -0.16 | -0.13 | -0.10 |
| EPS Diluted | -0.35 | -0.32 | -0.28 | -0.23 | -0.17 |
| Normalized Diluted EPS | -0.19 | -0.18 | -0.16 | -0.13 | -0.10 |
| Average Basic Shares Outstanding | 2.91B | 2.87B | 2.84B | 2.81B | 2.80B |
| Average Diluted Shares Outstanding | 2.91B | 2.87B | 2.84B | 2.81B | 2.80B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |